CORRESP Filing
Lite Strategy, Inc.
Date: Sept. 3, 2025 · CIK: 0001262104 · Accession: 0000929638-25-003343
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289312
Letter
Re:
MEI Pharma, Inc. 9920 Pacific Heights Blvd., Suite 150 San Diego, CA 92121
September 3, 2025
VIA EDGAR TRANSMISSION
Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Esq.
MEI Pharma, Inc. Registration Statement on Form S-3 Filed August 6, 2025 (amended August 26, 2025) File No. 333-289312
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-289312), so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on September 5, 2025, or as soon as practicable thereafter.
MEI PHARMA, INC.
By: /s/ Justin J. File Name: Justin J. File Title: Acting Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm MEI Pharma, Inc. 9920 Pacific Heights Blvd., Suite 150 San Diego, CA 92121 September 3, 2025 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Esq. Re: MEI Pharma, Inc. Registration Statement on Form S-3 Filed August 6, 2025 (amended August 26, 2025) File No. 333-289312 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-289312), so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on September 5, 2025, or as soon as practicable thereafter. MEI PHARMA, INC. By: /s/ Justin J. File Name: Justin J. File Title: Acting Chief Executive Officer